COMPASS Pathways plc (NASDAQ:CMPS) Short Interest Update

COMPASS Pathways plc (NASDAQ:CMPS) was the target of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 4,240,000 shares, a growth of 17.5% from the May 31st total of 3,610,000 shares. Based on an average daily volume of 497,900 shares, the short-interest ratio is currently 8.5 days.

Insider Activity

In other news, major shareholder George Jay Goldsmith sold 9,621 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $8.29, for a total value of $79,758.09. Following the completion of the sale, the insider now directly owns 3,966,052 shares of the company’s stock, valued at approximately $32,878,571.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders sold 59,252 shares of company stock valued at $514,183. Insiders own 4.25% of the company’s stock.

Institutional Investors Weigh In On COMPASS Pathways

Institutional investors and hedge funds have recently modified their holdings of the company. ARK Investment Management LLC grew its holdings in shares of COMPASS Pathways by 7.6% in the 4th quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock worth $22,915,000 after acquiring an additional 186,040 shares during the period. Affinity Asset Advisors LLC acquired a new stake in shares of COMPASS Pathways in the 4th quarter worth approximately $4,812,000. Armistice Capital LLC acquired a new stake in shares of COMPASS Pathways in the 3rd quarter worth approximately $2,960,000. Quest Partners LLC acquired a new stake in shares of COMPASS Pathways in the 4th quarter worth approximately $33,000. Finally, Jump Financial LLC acquired a new stake in shares of COMPASS Pathways in the 4th quarter worth approximately $371,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Stock Performance

Shares of CMPS stock opened at $6.04 on Friday. The company has a market cap of $413.02 million, a price-to-earnings ratio of -2.55 and a beta of 2.32. The stock has a 50 day simple moving average of $7.46 and a 200-day simple moving average of $8.87. COMPASS Pathways has a 12-month low of $5.01 and a 12-month high of $12.75. The company has a current ratio of 15.23, a quick ratio of 15.23 and a debt-to-equity ratio of 0.12.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.03). On average, equities analysts forecast that COMPASS Pathways will post -2.24 EPS for the current year.

Analyst Ratings Changes

Several analysts have commented on CMPS shares. HC Wainwright reaffirmed a “buy” rating and set a $120.00 price objective on shares of COMPASS Pathways in a research note on Monday, May 13th. Morgan Stanley started coverage on COMPASS Pathways in a research note on Monday, April 1st. They set an “overweight” rating and a $30.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a research note on Friday, June 21st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways currently has a consensus rating of “Buy” and a consensus price target of $47.40.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.